SCHEMBL1508047

SCHEMBL1508047

CNC(=O)OC(c1ccc(F)cc1)(c1ccccc1F)C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.40
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
MGLL Q99685 1/20 0.34
REN P00797 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
KCNH2 Q12809 1/20 0.33
CACNA1G O43497 1/20 0.32
USP2 O75604 1/20 0.32
TSHR P16473 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
EPHX1 P07099 1/20 0.32
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507915 0.87 NPC1 (0.40) NPC1RAB9AKMT2AMEN1KCNH2
SCHEMBL1507988 0.86 KCNN4 (0.36) KCNN4KCNE1KCNQ1NPC1RAB9A
SCHEMBL12833799 0.75 KCNN4 (0.40) KCNN4KCNE1KCNQ1NPC1RAB9A
SCHEMBL1507985 0.74 KCNN4 (0.41) KCNN4KCNE1KCNQ1NPC1RAB9A
SCHEMBL12833788 0.71 KCNN4 (0.42) KCNN4NPC1RAB9AKMT2AMEN1
SCHEMBL1507903 0.67 POLB (0.43) NPC1RAB9AKMT2AMEN1TSHR
SCHEMBL1508264 0.67 SMN1; SMN2 (0.43) KCNN4NPC1RAB9AKMT2AMEN1
SCHEMBL12834650 0.66 ALDH1A1 (0.41) KCNN4NPC1RAB9AKMT2AMEN1
SCHEMBL4241540 0.64 CHRM3 (0.51) NPC1RAB9AKMT2AMEN1
SCHEMBL1508133 0.64 RAB9A (0.40) NPC1RAB9AKMT2AMEN1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP claimed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US claimed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US claimed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP claimed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO claimed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US disclosed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP disclosed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009816-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 KCNN4 48/4885KCNE1 29/4885KCNQ1 2/4885
US-20070161607-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 KCNN4 48/4885KCNE1 29/4885KCNQ1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.